Skip to content. | Skip to navigation

University of Piemonte Orientale

Personal tools

You are here: Home / Teachers / Fabrizio FAGGIANO / Fabrizio FAGGIANO: List of publications

Navigation

Fabrizio FAGGIANO: List of publications

  1. Costa G, De Blasi S, Faggiano F, Segnan N. Stato di salute della popolazione di Torino: compendio della relazione sanitaria anno 1982. USL 1-23 di Torino, Torino, pp. 1-44, 1984.
  2. Rosso S, Segnan N, Colombo S, Costa G, De Maria M, Faggiano F, Fornero G. Stato di salute della popolazione di Torino: l'attività degli ospedali di Torino. USL 1-23 di Torino, Torino, pp. 1- 274, 1984.
  3. De Blasi S, Faggiano F, Leone M, Segnan N. La collaborazione del medico di base per aumentare la rispondenza dei controlli in una indagine epidemiologica. Bollettino Epidemiologica dell'USL 1-23 di Torino, 221-28, 1984.
  4. Cappa APM, Bertiond G, Colombo A, Faggiano F, Gussio M, Merletti F, Terracini B, Boffetta P. Incidence of breast cancer in Piedmont 1979-81. Tumori 1987; 73:219-227. (IF 2007: 0.597) (5°quint)
  5. Gallino G, Rinaudo A, Cabutto F, Fantini M, Frigessi D, Bachelet C, Sorrentino L, Maggiorotti P, Boffetta P, Faggiano F. La rappresentazione sociale della malattia mentale. USL 1-23 di Torino, Torino, pp. 1-39 + 1-23, 1987.
  6. D'Ambrosio R, Faggiano F, Colombo A, Motta M. Stato di salute e determinanti del ricovero in casa di riposo della popolazione anziana a Torino. U.S.L. 1-23 di Torino, Torino, 1987.
  7. Faggiano F, Zanetti R. L'epidemiologia dei tumori primitivi del fegato. Minerva Chirurgica, Torino, 1987.
  8. Zanetti R, Rosso R, Roffino R, Faggiano F, Colonna S, Martina G. Etude cas-témoins sur le mélanome de la peau dans la province de Turin. Revue d'Epidemiologie et de Santé Publique 1988; 36: 309- 317. (IF 2007: 0.570) (5°quint)
  9. Faggiano F, Joris F, Hohl J. Interès épidémiologiques à la base de la création d'un registre des tumeurs en Valais, Suisse. Epidémiologie du cancer dans les pays de langue latine. Rapport technique du CIRC N. 7, 223-227, Centre International sur le Cancer, Lyon, 1990. p. 223-227.
  10. Vineis P, Faggiano F, Terracini B. Biochemical epidemiology: uses in the study of human carcinogenesis. Teratogenesis, Carcinogenesis and Mutagenensis 1990; 10: 231-237.
  11. Merletti F, Faggiano F, Boffetta P, Amasio E, Rombolà A, Tabaro G, Terracini B. Topographical classification, clinical characteristics and diagnostic delay of cancer of larynx/hypopharynx in the city of Torino, Italy. Cancer 1990; 66: 1711-1716. (IF 2007: 4.632) (1°quint)
  12. Faggiano F, Costa G. Classe sociale e mortalità a Torino negli anni 80. POLIS 1990; IV: 471-496.
  13. Vineis P, Faggiano F, Tedeschi M, Ciccone G. Incidence rates of lymphomas and soft-tissue sarcomas and environmental measurements of phenoxy herbicides. Journal of the National Cancer Institute 1991; 83: 362-363. (IF 2007: 15.678) (1°quint)
  14. Lehmann W, Raymond L, Faggiano F, Sancho-Garnier H, Blanchet F, Del Moral A, Zubiri L, Terraccini B, Berrino F, Pequignot G, Esteve J, Tuyns A. Cancer of the Endolarynx, Epilarynx and Hypopharynx in south-western Europe: assessment of tumoral origin and risck factors. Advances in Oto-rhino-laryngology 1991; 46: 145-156.
  15. Vineis P, Faggiano F. Epidemiological models and prevention of cancer. Annals of Oncology 1991; 2: 559:563. (IF 2007: 4.875) (1°quint)
  16. Cappa APM, Faggiano F, Gussio M, Luparia P, Merletti F, Toniolo P, Palazzo Z, Terracini B, Zanetti R. Incidenza del cancro della mammella femminile in Piemonte negli anni 1979-1981. Regione Piemonte e AIRC, 1991
  17. Costa G, Faggiano F, Brussolo S, Giraudo AM. Le differenze sociali di fronte alla morte: la realtà di Torino. Notiziario di statistica 1992; 1/92, Torino.
  18. Costa G, Faggiano F. Le differenze sociali nella salute in Italia. Politica ed economia 1992; 2: 3-5.
  19. Micheli A, Baldasseroni A, Bruzzi P, Faggiano F, Gatta G, Ivaldi C, Magnani C, Merletti F, Ninu B, Sant M. La sopravvivenza per tumori dell'apparato respiratorio: dati italiani su base di popolazione e confronti internazionali. Ann Ist Super Sanità 1992; 28: 71-90.
  20. Costa G, Faggiano F, Lemma P, Renga G. Classi sociali, emarginati, stranieri: antiche e nuove diseguaglianze. Igiene Moderna 1992; 98: 33-39.
  21. Faggiano F, Vicari P, Gogliani F, Zanetti R, Costa G. Differenze sociali nella frequenza di tumori a Torino. In: Epidemiologie du cancer dans les pays del langue latine, Rapport Technique du CIRC N° 12, 1992.
  22. Hohl J, Faggiano F, Joris F. Premiers résultats d’incidence du Registre Valaisan des Tumeurs: qualité de la récolte des données et estimation de l’exhaustivité à l’aide de la méthode capture-recapture. In: Epidemiolgie du cancer dans les pays del langue latine, Rapport Technique du CIRC N° 12, 1992.
  23. Faggiano F, Vineis P, Cravanzola D, Pisani P, Xompero G, Riboli E, Kaaks R. Validation of a method for the estimation of food portion size. Epidemiology 1992, 3, 379-382. (IF 2007: 5.283) (1°quint)
  24. Vineis P. Faggiano F, Riboli E, Berrino F, Pisani P, Crosignani P. Dietary habits, internal migration and social class in a sample of a northern italian population. Tumori 1992, 78, 235-238. (IF 2007: 0.597) (5°quint)
  25. Costa G, Faggiano F. Diseguaglianze sociali, salute e sopravvivenza. Tutela 1993; VIII(2/3):59-63.
  26. Costa G., Faggiano F. Le differenze sociali nella mortalità in Italia. SNOP 1993, 27:4-7.
  27. Faggiano F, Zanetti R, Costa G. Cancer risk and social inequalities in Italy. J of Epidemiol and Community Health 1994; 48; 447-452. (IF 2007: 2.956) (1°quint)
  28. Biocca M, Ferro S, Costa G, Faggiano F. A training project in epidemiology in prevention services of the Emilia Romagna region. Epidemiologia & Prevenzione 1994; 18:121-124.
  29. Faggiano F, Renga G. Efficacia sanitaria e indicatori nel sistema sanitario nazionale. Organizzazione Sanitaria 1994, 3/4:38-46.
  30. Davoli M, Perucci, CA, Bargagli AM, D’Ippoliti D, Faggiano F, Merlo G. La mortalità nei tossicodipendenti. Osservatorio delle leggi sulla droga, XI rapporto, 1994, ed Millelire-Stampa Alternativa, 1994.
  31. Costa G, Faggiano F. Differenze sociali e salute. Salute e Territorio 1994;93:6-13.
  32. Ciccone G, Faggiano F, Falasca P. Inquinamento atmosferico da SO2 e ricoveri ospedalieri a Ravenna: un’analisi caso-controllo. Epidemiologia & Prevenzione 1995; 19:99-104.
  33. Faggiano F, Bonetti C, Costa G. Differenze sociali nella salute: una sintesi. Professione 1995, 5/94, 11-14.
  34. Faggiano F, Lemma P, Costa G, Gnavi R, Pagnanelli F. Cancer mortality by educational level in Italy. Cancer Causes and Control 1995; 6: 311-320. (IF 2007: 3.279) (1°quint)
  35. Faggiano F, Renga G, Scarmozzino A. Linee-guida e formazione in medicina. La Formazione del Medico 1995; 9: 91-93.
  36. Faggiano F, Renga G. Quale formazione alle linee-guida per la pratica medica? MEDIC 1996; 4:43-49.
  37. Faggiano F, Costa G, Lemma P. L’equità nella salute della popolazione anziana. Organizzazione Sanitaria 1996; anno XX n° 1-2: 46-57.
  38. Ciccone G, Magnani C, Dalmasso P, Volante TF, Faggiano F, Camerlengo A et al. Asthma, respiratory disorders and environment. Rivista Italiana di Pediatria-Italian Journal of Pediatrics 1996; 22: 475-477
  39. Faggiano F, Seniori Costatini A, Costa G. Differenze sociali e salute della donna in Italia. Epidemiologia & Prevenzione 1996; 20: 251-254.
  40. Ciminale M, Lemma P, Faggiano F. Differenze di genere negli esiti della tossicodipendenza a Torino. Epidemiologia & Prevenzione 1996; 20: 267-268.
  41. Ciminale M, Faggiano F, Scarmozzino A. La salute è uguale per tutti? Prospettive Assistenziali 1996; 115:10-14.
  42. Kunst AE, Cavelaars AEJM, Groenhof F, Geurts JJM, Mackenbach JP and the EU Working Group on Socioeconomic Inequalities in Health. Socioeconomic inequalities in morbidity and mortality in Europe: a comparative study - Vol 1: Main Report. Erasmus University 1996.
  43. Kunst AE, Cavelaars AEJM, Groenhof F, Geurts JJM, Mackenbach JP and the EU Working Group on Socioeconomic Inequalities in Health. Socioeconomic inequalities in morbidity and mortality in Europe: a comparative study - Vol 2: Working documents. Erasmus University 1996.
  44. Kunst AE, Cavelaars AEJM, Groenhof F, Geurts JJM, Mackenbach JP and the EU Working Group on Socioeconomic Inequalities in Health. Socioeconomic inequalities in morbidity and mortality in Europe: a comparative study - Vol 3: Country reports. Erasmus University 1996.
  45. Kunst AE, Cavelaars AEJM, Groenhof F, Geurts JJM, Mackenbach JP and the EU Working Group on Socioeconomic Inequalities in Health. Socioeconomic inequalities in morbidity and mortality in Europe: a comparative study - Vol 4: Determinants. Erasmus University 1996.
  46. Pisani P, Faggiano F, Krogh V, Palli D, Vineis P, Berrino F. Relative validity and reproducibility of a food-frequency dietary questionnaire for use in the Italian Epic Centres. Int J Epidemiology 1997; 26: S152-S159. (IF 2007: 5.151) (1°quint)
  47. Beccastrini S, Biocca M, Costa G, Faggiano F, Grillo S, Magelli L, Occhipinti E, Renga G, Zampillo P, Perticaroli S, Roseo G, Chierichetti F. Analisi del fabbisogno formativo per l’accesso ai ruoli direttivi del servizio sanitario nel settore prevenzionale. Ispesl, Roma, Allegato a Fogli di informazione 1997, 4:1-83.
  48. Rosso S, Faggiano F, Zanetti R, Costa G. Social class and cancer survival in Turin (Italy). Journal of Epidemiology and Community Health 1997; 51:30-34. (IF 2007: 2.956) (1°quint)
  49. Mackenbach JP, Kunst AE, Cavelaars AEJM Groenhof F, Geurts JJM and the EU Working Group on Socioeconomic Inequalities in Health. Socioeconomic inequalities in morbidity and mortality in western Europe. The Lancet 1997; 349: 1657-1659. (IF 2007: 28.638) (1°quint)
  50. Boffetta P, Merletti F, Faggiano F, Migliaretti G, Ferro G, Zanetti R, Terracini B. Prognostic factors and survival of laryngeal cancer patients from Turin, Italy. Am J Epidemiol 1997; 145:1100-1105. (IF 2007: 5.285) (1°quint)
  51. Todros T, Faggiano F, Chiappa E, Gaglioti P, Mitola B, Sciarrone A and the Gruppo Piemontese for prenatal screening of congenital heart disease. Accuracy of routine ultrasonography in screening heart disease prenatally. Prenatal Diagnosis 1997; 17:901-906. (IF 2007: 1.319) (1°quint)
  52. Gruppo ESEDRA. Mortalità tra i tossicodipendenti: studio multicentrico italiano. Epidemiologia & Prevenzione 1997; 21: 265-271.
  53. Gruppo SIDRIA. La frequenza dei fattori di rischio per l’asma bronchiale in varie aree italiane. Epidemiologia & Prevenzione 1997; 21: 243-251.
  54. Gruppo SIDRIA. La frequenza dell’asma pediatrico in diverse aree italiane di SIDRIA. Epidemiologia & Prevenzione 1997; 21: 235-241.
  55. SIDRIA (Italian Studies on Respiratory Disorders in Childhood ans the Environment). Asthma and respiratory symptoms in 6-7 yr old Italian children: gender, latitude, urbanization and socioeconomic factors. Eur Respir J 1997; 10; 1780-1786. (IF 2007: 5.349) (1°quint)
  56. Faggiano F, Costa G, Lemma P. L’equità nella salute della popolazione anziana. In: La salute degli anziani in Italia. Monografie CNR-IRP 7/1997.
  57. Joris F, Faggiano F, de Weck D. Le cancer en Valais 1989-1993. Sion (CH), 1997.
  58. Faggiano F, Vietti A, Armaroli P. Alcool e mortalità: risultati di una rassegna della letteratura medica 1981-1998. Professione 1998;VI:29-35.
  59. Kunst AE, Groenhof F, Borgan JK, Costa G, Desplaques G, Faggiano F, et al. Socio economic inequalities in mortality. Methodological problems illustrated with three examples from Europe. Revue d'Epidemiologie et de Santé Publique 1998, 46: 467-479. (IF 2007: 0.570) (5°quint)
  60. Kunst AE, del Rios M, Groenhof F, Mackenbach JP for the European Union Working Group on Socioeconomic Inequalities in Health. Socioeconomic inequalities in stroke mortality among middle-aged men: an international overview. Stroke 1998; 29: 2285-2291. (IF 2007: 6.296) (1°quint)
  61. Kunst AE, Groenhof F, Mackenbach JP and the European Union Working Group on Socioeconomic Inequalities in Health. Occupational class and cause specific mortality in middle aged men in 11 European countries: comparison of population based studies. BMJ 1998, 316; 1636-1641. (IF 2007: 9.723) (1°quint)
  62. Kunst AE, Groenhof F, Mackenbach JP and the European Union Working Group on Socioeconomic Inequalities in Health. Mortality by occupational class among men 30-64 years in 11 European countries. Soc Sci Med 1998, 46; 1459-1476. (IF 2007: 2.453) (1°quint)
  63. Kunst AE, Groenhof F, Andersen O, Borgan JK, Costa G, Desplaques G, Filakti H, do R. Giraldes M, Faggiano F, et al. Occupational class and ischemic health disease mortality in the United States and in 11 European Countries. Am J Public Health 1999, 89: 47-53. (IF 2007: 3.612) (1°quint)
  64. Mackenbach JP, Kunst AE, Groenhof F, Borgan JK, Costa G, Faggiano F, Jòzan P, Leinsalu M, Martikainen P, Rychtarikova J, Valkonen T. Socioeconomic inequalities in mortality among women and among men: an international study. Am J Public Health 1999, 89: 1800-6. (IF 2007: 3.612) (1°quint)
  65. Costa G, Cadum E, Faggiano F, Cardano M, Demaria M. Le diseguaglianze sociali nella mortalità per malattie cardiovascolari in Italia. Giornale Italiano di Cardiologia 1999; 29:684-691.
  66. Faggiano F, Di Stanislao F, Lemma P, Renga G. Role of social class in caries occurrence in 12 year olds in Turin, Italy. Eur J of Public Health 1999, 9:109-113. (IF 2007: 1.910) (2°quint)
  67. Todros T, Preve CU, Bontempo S, Plazzotta C, Lombardo P, Biolacati M, Verdiglione P, Faggiano F. Delivery after one previous caesarean section. It J Gynaecol Obstet 1999;2: 57-61
  68. Faggiano F, Zanetti R, Rosso S, Costa G. Differenze sociali nell’incidenza, letalità, mortalità per tumori a Torino. Epidemiologia & Prevenzione 1999; 23: 294-299.
  69. Siliquini R, Faggiano F, Renga G. Ecstasy: stima aggiornata dei danni alla salute. MTD – It J Addiction 1999; 22-23: 5-9.
  70. Petignat P, Gaudin G, Vajda D, Stalder M, Rey JP, Faggiano F, de Weck D, Joris F, Obrist R. Advanced stage (FIGO III-IV) epithelial ovarian cancer: multivariate analysis of prognostic factors in an area without tertiary referral oncology center. A population based study. Onkologie 1999; 22:406-410. (IF 2007: 1.227) (5°quint)
  71. Vannoni F, Burgio A, Quattrociocchi L, Costa G, Faggiano F. Differenze sociali e indicatori di percezione di salute, malattie croniche disabilità e stili di vita, nella indagine Multiscopo Istat 1994. Epidemiologia & Prevenzione 1999;23:215-29
  72. Renga G, Lemma P, Faggiano F, Siliquini R. Logiche e modelli della sanità pubblica. L’Igiene Moderna 1999; 112:1147-62.
  73. Faggiano F. Privacy e ricerca storica: la ricerca epidemiologica. Passato e Presente 2000; 50; 42-44
  74. Bruno G, Pagano G, Faggiano F, De Salvia A, Merletti F. Effect of Sardinian heritage on risk and age at onset of type 1 diabetes: a demographic case-control study of Sardinian migrants. Int J Epidemiol 2000; 29:532-5. (IF 2007: 5.151) (1°quint)
  75. Faggiano F, Renga G, Versino E. I determinanti delle disuguaglianze sociali nella salute in Italia. Ann Ig 2000 (suppl 1): 67-74
  76. Mackenbach JP, Cavelaars AEJM, Kunst AE, Groenhof F and the EU Working Group on Socioeconomic Inequalities in Health. Socioeconomic inequalities in cardiovascular disease mortality. European Hearth Journal 2000; 21: 1141-51. (IF 2007: 7.924) (1°quint)
  77. Ferri M, Davoli M, Farrell M, Faggiano F, Ali R, Auriacombe M, Mattick R, Ling W. Il gruppo di revisione Cochrane su droghe e alcol. Medicina delle Tossicodipendenze 2000; VIII:54-56.
  78. Davoli M, Ferri M, Ali R, Auriacombe M, Faggiano F, Mattick R, Farrell M, Ling W. The Cochrane Review Group on Drugs and Alcohol. Addiction 2000; 95: 1473-1474. (IF 2007: 4.014) (1°quint)
  79. Mattick R, Ali R, Auriacombe M, Davoli M, Faggiano F, Farrell M, Ferri M, Ling W. Cochrane Drugs and Alcohol Group: The development of systematic reviews of treatment-outcome. Alcohol and alcoholism 2001; 36(2); 109-111. (IF 2007: 2.092) (3° quint)
  80. Durelli L, Oggero A, Verdun E, Isoardo GL, Barbero P, Bergamasco B, Brossa PC, Ghigo E, Maccario M, Faggiano F. Betaferon Safety Trial (BEST) Study Group. Thyroid function and anti-thyroid antibodies in MS patients screened for interferon treatment. A multicenter study. J Neurol Sci 2001;193(1):17-22. (IF 2007: 2.315) (2° quint)
  81. Ferri M, Davoli M, Ali R, Auriacombe M, Faggiano F, Farrell M, Ling W, Mattick R. Il gruppo Cochrane su Droga ed Alcool. Medicina delle Tossicodipendenze 2000; 1
  82. Faggiano F, Versino E, Lemma P. Decennial trends of social differentials in smoking habits in Italy. Cancer Causes and Control 2001; 12:665-671. (IF 2007: 3.279) (1°quint)
  83. Siliquini R, Faggiano F, Geninatti S, Versino E, Mitola B, Ippolito R. Patterns of drug use among young men in Piedmont (Italy). Drug Alcohol Depend 2001; 64:329-335 (IF 2007: 3.222) (1°quint)
  84. Faggiano F, Lemma P, Borraccino A, Angius P, Ippolito R, Versino E. School-based prevention for illicit drugs' use (Protocol for a Cochrane Review). Cochrane Database of Systematic Reviews 2001, Issue 2. Oxford: Update Software. (IF 2007 4.654) (1°quint)
  85. Spadea T, Faggiano F, Armaroli P, Maina L, Costa G. Effect of socioeconomic factors and fetal growth on adult mortality and morbidity. J Epidemiol Community Health 2001; 55 (supplement I): A25-n.94. (IF 2007: 2.956) (1°quint)
  86. Ali R, Auriacombe M, Davoli M, Faggiano F, Farrell M, Ferri M, Ling W, Mattick R. Systematic Reviews of Scientific Literature on Interventions on Drug and Alcohol Addiction: the Cochrane Review Group on Drugs and Alcohol. Drug and Alcohol Dependence 2001; 63 Supplement 1 (IF 2003: 3.222) (1°quint)
  87. Ferri M, Davoli M, Ali R, Auriacombe M, Faggiano F, Farrell M, Ling W, Mattick R. Il gruppo Cochrane su Droga ed Alcool. Bollettino delle Tossicodipendenze e l'Alcoolismo 2001;2
  88. Durelli L, Verdun E, Barbero P, Bergli M, Versino E, Grezzi A, Montanari E, Zafferani M, and the INdependent COMparison of INterferon (INCOMIN) Trial Study Group. Every-other-day interferon beta 1b versus onc-weekly interferon beta-1° for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). The Lancet 2002; 359: 1453-60. (IF 2007: 28.638) (1°quint)
  89. Faggiano F. Disegni di studio di coorte per la valutazione di efficacia di interventi sanitari. Decidere in Medicina 2003; 2: 40-44.
  90. Faggiano F, Vigna-Taglianti F, Versino E, Lemma P. Methadone maintenance at different dosages for opiod dependence (Cochrane Review). Cochrane Database of Systematic Reviews 2003; 3. Oxford: Update Software. (IF 2007 4.654) (1°quint)
  91. de Weck D, Faggiano F, Tiab L, Pury P, Joris F, Luthi J-C. Le cancer en Valais 1994-1998. Dep Santé Etat du Valais. Sion, 2003
  92. Dirindin N, Costa G e Faggiano F. Assessing Public Action in Europe: Health Policies, Quaderni del Dipartimento di Scienze Economiche e Finanziarie “G. Prato”, Università di Torino. Torino 2003.
  93. Piccoli GB, Mezza E, Grassi G, Faggiano F, Calderini M, Sampo' D, Gentile L. Dialysis and transplantation for end-stage renal disease in adults (Protocol for a Cochrane Review). Cochrane Database of Systematic Reviews 2003, Issue 2. Oxford: Update Software. (IF 2007 4.654) (1°quint)
  94. Faggiano F, Vigna-Taglianti F, Versino E, Salamina G, Bugiani M. (2004). Tuberculosis incidence in Turin Italy, 1973-1999. International Journal of Tuberculosis and Lung Disease 2004; 8: 171-179. (IF 2007: 2.240) (3°quint)
  95. Carcieri A, Cuomo L, Faggiano F. Mortalità droga-correlata fra i giovani adulti in Italia: 1980-2001. Medicina delle Tossicodipendenze/Italian Journal of Addictions 2004; 43-44:25-38.
  96. Rocca P, Calvarese P, Faggiano F, Marchiaro L, Mathis  F, Rivoira E, Tarocco B, Bogetto F. Citalopram versus sertraline in late-life non-major clinically significant depression: a one-year follow-up clinical trial. Journal of Clinical Psychiatry 2005; 66: 360-369 (IF 2007: 5.060) (1°quint)
  97. Bargagli AM, Davoli M, Schifano P, Faggiano F, Perucci CA and the Vedette study group Determinants of methadone treatment assignment among heroin addicts on first admission to public treatment centres in Italy. Drug and Alcohol Dependence 2005; 79: 191–199. (IF 2007: 3.222) (1°quint)
  98. Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat. 2005; 28:321-9
  99. Faggiano F, Vigna-Taglianti FD, Versino E, Zambon A, Borraccino A, Lemma P. School-based prevention for illicit drugs' use. Cochrane Database of Systematic Reviews 2005; issue 2:CD003020 . (IF 2007 4.654) (1°quint)
  100. Diecidue R, Iannaccone A, Lampis F, Mathis F, Davoli M, Bargagli AM, Faggiano F. Studio VEdeTTE - Monografia 3: Studio Pilota VEdeTTE 2. Torino 2005
  101. Mathis F, Bargagli AM, Scarmozzino A, Davoli M, Versino E, Piras G, Faggiano F, Pani PP, Martini C, Cauda V. Studio VEdeTTE - Monografia 2: Studio Pilota VEdeTTE 1. Torino, 2005
  102. Versino E, Bargagli AM, Salamina G, Amato L, Mathis F, Piras G, Cuomo L, Schifano P, Faggiano F, Davoli M. Monografia n. 4 - Analisi descrittiva della coorte arruolata nei primi 18 mesi dello studio. Torino 2005
  103. Vigna-Taglianti F, Bargagli AM, Mathis F, Schifano P, Decidue R, Amato L, Salamina G, Piras G, Cuomo L, Davoli M, Faggiano F, Belleudi V. Monografia n. 5 - Analisi dei trattamenti dei primi 18 mesi dello studio. Torino 2005
  104. Vigna-Taglianti F, Vineis P, Liberati A, Faggiano F. Quality of systematic reviews used in guidelines for oncology practice. Annals of Oncology 2006; 17: 691-701 (IF 2007: 4.875) (1°quint)
  105. Schifano P, Bargagli AM, Belleudi V, Amato L, Davoli M, Diecidue R, Versino E, Vigna-Taglianti F, Faggiano F, Perucci CA. Methadone treatment in clinical practice in Italy: need for improvement. Eur Addict Res 2006;12(3):121-7.
  106. Oggé G, Gaglioti P, Maccanti S, Faggiano F, Todros T and the Gruppo Piemontese for Prenatal Screening of Congenital Heart Disease. Prenatal screening for congenital heart disease with four-chamber and outflow-tract views: a multicenter study. Ultrasound Obstet Gynecol 2006; 28: 779–784 (IF 2007 2.672) (1°quint)
  107. Faggiano F, Vigna-Taglianti F. Systematic reviews of effectiveness of Public Health practice. Italian Journal of Public Health 2006; 3: 29-33
  108. Leone MA, Avanzi GC, Lo Iacono A, Vigna-Taglianti F, Faggiano F. Gamma-hydroxybutyrate (GHB) for prevention and treatment of alcohol withdrawal. (Protocol) Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD006266. DOI: 10.1002/14651858.CD006266. (IF 2007 4.654) (1°quint)
  109. Bargagli AM. Faggiano F. Amato L. Salamina G. Davoli M. Mathis F. Cuomo L. Schifano P. Burroni P. Perucci CA. For The VEdeTTE Study Group. VEdeTTE, a Longitudinal Study on Effectiveness of Treatments for Heroin Addiction in Italy: Study Protocol and Characteristics of Study Population. Substance Use & Misuse 2006 41:1861-79 (IF 2007: 1.229) (4°quint)
  110. Faggiano F, Vigna-Taglianti F, Bohrn K, Richardson C, Burkhart  G, Fabiani L, Lindahl AM, Melero JC, Panella M, Perez T, Siliquini R, Van Der Kreeft P, Wiborg G, Yotsidi V, Vasara M, Cuomo L. An effective school-based prevention programme for tobacco, alcohol, and drugs: the EU-Dap cluster randomized trial. European Journal of Public Health 2006; 16 (S1): 75-76. (IF 2007 1.910) (2°quint)
  111. Faggiano F, Vigna-Taglianti F. Quale valutazione per il sistema dei servizi per le tossicodipendenze? Bollettino per le Farmacodipendenze e l’Alcoolismo 2006. XXIX (3-4): 14-19.
  112. Faggiano F, Richardson C, Bohrn K, Galanti MR and the EU-Dap Study Group. A cluster randomized controlled trial of school-based prevention of tobacco, alcohol and drugs use: the EU-Dap design and study population. Preventive Medicine 2007; 44: 170–173. (IF 2007: 2.314) (2°quint)
  113. Galanti MR, Siliquini R, Cuomo L, Meleto JC, Perez T, Panella M, Faggiano F and the EU-DAP study group. Testing anonymous link procedures for follow-up of adolescents in a school-based trial: the EU-Dap pilot study. Preventive Medicine 2007; 44: 174–177. (IF 2007: 2.314) (2°quint)
  114. Vigna-Taglianti FD, Mathis F, Diecidue  R, Burroni P, Iannaccone A, Lampis F, Zuccaio P, Pacifici R, Versino E, Davoli M, Faggiano F. A follow-up study of heroin addicts (VEdeTTE2): study design and protocol. Substance Abuse Treatment, Prevention, and Policy 2007; 2:9 (15 Mar 2007). doi:10.1186/1747-597X-2-9
  115. Davoli M, Bargagli AM, Perucci CA, Schifano P, Belleudi V, Hickman M, Salamina G, Diecidue R, Vigna-Taglianti F & Faggiano F. Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study. Addiction 2007; 102: 1954–1959. (IF 2007: 4.014) (1°quint)
  116. Zambon A, Vigna-Taglianti F, Versino E, Borraccino A, Mathis F, Lemma P, Faggiano F. Gli interventi educativi in ambito scolastico nella prevenzione dell’uso di sostanze illecite: una revisione Cochrane per valutarne l’efficacia. Ed San & Prom alla Salute 2007; 30: 133-145
  117. Ferri M, Bargagli AM, Faggiano F, Belleudi V, Salamina G, Vigna-Taglianti F, Davoli M, Perucci CA, Gruppo Studio VEdeTTE*. Mortalità in una coorte di tossicodipendenti da eroina arruolati presso i Ser.T in Italia, 1998-2001. Epidemiologia & Prevenzione 2007; 31(5): 276-282.
  118. Faggiano F, Vigna-Taglianti F, Versino  E, Zambon A, Borraccino A, Lemma P. School-based prevention for illicit drugs use: A systematic review. Preventive Medicine 2008; 46: 385–396. (IF 2007: 2.314) (2°quint)
  119. Gontero P, Ceratti G, Guglielmetti S, Andorno A, Terrone C, Bonvini D, Faggiano F, Tizzani A, Frea B, Valente G. Prognostic factors in a prospective series of papillary renal cell carcinoma. British Journal of Urology 2008;102:697-702. (IF 2007 2.751) (2°quint)
  120. Clerico M, Faggiano F, Palace J, Rice G, Tintorè M, Durelli L. Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. Cochrane Database Syst Rev 2008 Apr 16;(2):CD005278. Review. (IF 2007 4.654) (1°quint)
  121. Sogni F, Brausi M, Frea B, Martinengo C, Faggiano F, Tizzani A, Gontero P. Morbidity and quality of life in elderly patients receiving ileal conduit or orthotopic neobladder after radical cystectomy for invasive bladder cancer. Urology 2008;71:919-23. (IF 2007 2.134) (2°quint)
  122. Faggiano F, Galanti MR, Bohrn K, Burkhart G, Vigna-Taglianti F, Cuomo L, Fabiani L, Panella M, Perez T, Siliquini R, van der Kreeft P, Vassara M, Wiborg  G, and the EU-Dap Study Group. The effectiveness of a school-based substance abuse prevention program: EU-Dap Cluster Randomised Controlled Trial. Preventive Medicine 2008; 47: 537-543 (IF 2007: 2.314) (2°quint)
  123. Faggiano F. Sono utili le Linee Guida per la tabaccologia? Tabaccologia 2008; 3: 7-8
  124. Spadea T, D’errico A, Demaria M, Faggiano F, Pasian S, Zanetti R, Rosso S, Vicari P, Costa G. Educational inequalities in cancer incidence in Turin, Italy. Eur J Cancer Prev. 2009, 18(3):169-78.
  125. Faggiano F and on behalf of the EU-Dap Study Group. Response to “Hypothesis testing and the EU-Dap evaluation of the unplugged curriculum”. PM 2009; http://dx.doi.org/10.1016/j.ypmed.2009.04.005
  126. Vigna-Taglianti F, Vadrucci S, Faggiano F, Burkhart G, Siliquini R, Galanti MR, EU-Dap Study Group. Is universal prevention against youths' substance misuse really universal? Gender specific effects in the EU-Dap school-based prevention trial. J Epidemiol Community Health 2009;63:722–728
  127. van der Kreeft P, Wiborg G, Galanti MR, Siliquini R, Bohrn K, Scatigna M, Lindahl A-M, Melero JC, Vassara M, Faggiano F. ‘Unplugged’: A new European school programme against substance abuse. Drugs: Education, Prevention and Policy 2009; 16(2): 167–181
  128. van Lenthe FJ, de Bourdeaudhuij I, Klepp K-I, Lien N, Moore L, Faggiano F, Kunst AE, Mackenbach JP. Preventing socioeconomic inequalities in health behaviour in adolescents in Europe: Background, design and methods of project TEENAGE. BMC Public Health 2009, 9:125
  129. Barbieri A, Vanhaecht K, Van Herck P, Sermeus W, Faggiano F, Marchisio S, Panella M. Effects of clinical pathways in the joint replacement: a meta-analysis. BMC Med. 2009 Jul 1;7(1):32
  130. Faggiano F, Vigna-Taglianti F, Burkhart G, Bohrn K, Cuomo L, Gregori D, Panella M, Scatigna M, Siliquini R, Varona L, van der Kreeft P, Vassara M, Wiborg G, Galanti MR; the EU-Dap Study Group. The effectiveness of a school-based substance abuse prevention program: 18-Month follow-up of the EU-Dap cluster randomized controlled trial. Drug Alcohol Depend 2010;108:56-64
  131. Leone MA, Vigna-Taglianti F, Avanzi G, Brambilla R, Faggiano F. Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses. Cochrane Database Syst Rev. 2010 Feb 17;2:CD006266.
  132. Salamina G, Diecidue R, Vigna-Taglianti F, Jarre P, Schefano P, Bargagli AM, Davoli M, Amato L, Perucci CA, Faggiano F and the VEdeTTE Study Group. Effectiveness of Therapies for Heroin Addiction in Retaining Patients in Treatment: Results From the VEdeTTE Study. Substance Use & Misuse 2010;45: 2076-92
  133. Faggiano F. Prevention of substance abuse: randomised or observational evaluation is absolutely needed. Adicciones. 2010;22(1):11-4.
  134. Davoli M, Faggiano F. The contribution of the Italian Epidemiology to the European research on drugs and alcohol. Epidemiol Prev. 2010 Sep-Dec;34(5-6):35-38.
  135. Amato L, Davoli M, Vecchi S, Ali R, Farrell M, Faggiano F, Foxcroft D, Ling W, Minozzi S, Chengzheng Z. Cochrane systematic reviews in the field of addiction: What's there and what should be. Drug Alcohol Depend 2011; 113: 96-103
  136. Caria MP, Faggiano F, Bellocco R, Galanti MR; EU-Dap Study Group. Effects of a school-based prevention program on European adolescents' patterns of alcohol use. J Adolesc Health. 2011 Feb;48(2):182-8.
  137. De Bourdeaudhuij I, Simon C, De Meester F, Van Lenthe F, Spittaels H, Lien N, Faggiano F, Mercken L, Moore L, Haerens L. Are physical activity interventions equally effective in adolescents of low and high socio-economic status (SES): results from the European Teenage project. Health Educ Res. 2011 Feb;26(1):119-30.
  138. Brown CH, Sloboda Z, Faggiano F, Teasdale B, Keller F, Burkhart G, Vigna-Taglianti F, Howe G, Masyn K, Wang W, Muthén B, Stephens P, Grey S, Perrino T; Prevention Science and Methodology Group. Methods for Synthesizing Findings on Moderation Effects Across Multiple Randomized Trials. Prev Sci. 2011 Mar 1. [Epub ahead of print]
  139. Faggiano F. Reaction to the article: Environmental drug prevention in the EU - why is it so unpopular? by Gregor Burkhart. Adicciones 2011; 23: 101-102
  140. Morgenstern M, Poelen EAP, Scholte R, Karlsdottir S, Jonsson SH, Mathis F, Faggiano F, Florek E, Sweeting H, Hunt K, Sargent JD, Hanewinkel R. Smoking in movies and adolescent smoking: cross-cultural study in six European countries. Thorax 2011;66(10):875-83
  141. Caria MP, Faggiano F, Bellocco R, Galanti MR. The influence of socioeconomic environment on the effectiveness of alcohol prevention among European students: a cluster randomized controlled trial. BMC Public Health. 2011 May 13;11:312.
  142. Monti S, Zuccaro V, De Vecchi F, Benech R, Allara E, Faggiano F and the Avogadro Vaccine Prevention Group. H1N1 2009 influenza vaccine prevention: a comparison between the Italian press and the scientific recommendations. Italian Journal of Public Health 2011; 8: 49-59
  143. Hanewinkel R, Sargent JD, Karlsdottir S, Hrafn Jonsson S, Mathis F, Faggiano F, Poelen EAP, Scholte R, Florek E, Sweeting E, Hunt K, Morgenstern M. High youth access to movies that contain smoking in Europe compared with the USA. Tobacco Control 2011. Ahead of printing. 10.1136/tobaccocontrol-2011-050050
  144. Millett C, Hanewinkel R, Britton J, Florek E, Faggiano F, Ness A, McKee M, Polansky JR, Glantz SA. European governments should stop subsidizing films with tobacco imagery. Eur J Public Health 2012; 22: 167-8
  145. Hanewinkel R, Sargent JD, Poelen EAP, Scholte R, Florek E, Sweeting E, Hunt K, Karlsdottir S, Hrafn Jonsson S, Mathis F, Faggiano F, Morgenstern M. Alcohol Consumption in Movies and Adolescent Binge Drinking in 6 European Countries. Pediatrics 2012; 129(4):709-20
  146. Brambilla R, Vigna-Taglianti F, Avanzi G, Faggiano F, Leone M. Il gamma-idrossibutirrato (GHB) nel trattamento a medio/lungo termine della dipendenza da alcol: una revisione sistematica. Rivista di Psichiatria 2012; 47: 269-280
  147. Muttarak R, Gallus S, Franchi M, Faggiano F, Pacifici R, Colombo P, La Vecchia C. Why do smokers start? Eur J Cancer Prev. 2013 Mar;22(2):181-6
  148. Morgenstern M, Sargent JD, Engels RCNE, Scholte RHJ, Florek E, Hunt K, Sweeting H, Mathis F, Faggiano F, Hanewinkel R. Smoking in Movies and Adolescent Smoking Initiation Longitudinal Study in Six European Countries. J Prev Med 2013;44(4):339 –344
  149. Caria MP, Faggiano F, Bellocco R, Galanti MR; the EU-Dap Study Group. Classroom characteristics and implementation of a substance use prevention curriculum in European countries. Eur J Public Health. 2013 Jan 18.
  150. Castro Sanchez AY, Aerts M, Shkedy Z, Vickerman P, Faggiano F, Salamina G, Hens N. A mathematical model for HIV and hepatitis C co-infection and its assessment from a statistical perspective. Epidemics. 2013 Mar;5(1):56-66]
  151. Gorini G, Carreras G, Allara E, Faggiano F. Decennial trends of social differences in smoking habits in Italy: a 30-year update. Cancer Causes Control. 2013 May 3. [Epub ahead of print]
  152. Galanti MR, Coppo A, Jonsson E, Bremberg S, Faggiano F. Anti-tobacco policy in schools: upcoming preventive strategy or prevention myth? A review of 31 studies. Tob Control. 2013 May 28. [Epub ahead of print]
  153. Ferri M, Allara E, Bo A, Gasparrini A, Faggiano F. Media campaigns for the prevention of illicit drug use in young people. Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD009287. DOI: 10.1002/14651858.CD009287.pub2.
  154. Bosi S, Gorini G, Tamelli M, Monti C, Storani S, Carreras G, Martini A, Allara E, Angelini P, Faggiano F. A school-based peer-led smoking prevention intervention with extracurricular activities: the LILT-LdP cluster randomized controlled trial design and study population. Tu mo ri, 99: 586-591, 2013
This is Schools Diazo Plone Theme